AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01892813
Drug: Nicotine replacement therapy - Transdermal nicotine patch
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Trial: NCT01892813
Drug: Nicotine replacement therapy - Nicotine gum
RxNorm normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Trial: NCT01892813
Drug: Nicotine replacement therapy - Nicotine lozenge
RxNorm normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Trial: NCT01892813
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Trial: NCT01892813
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Trial: NCT01892813
Drug: Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum
RxNorm normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Trial: NCT01892813
Drug: Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Trial: NCT01892813
Drug: Combination pharmacotherapy - Transdermal nicotine patch + bupropion
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Trial: NCT00545493
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
Trial: NCT01833897
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
Trial: NCT01833897
Drug: D-cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
Trial: NCT02234427
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-week aspirin therapy (81mg/day)
Trial: NCT02253199
Drug: intranasal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg.
Trial: NCT00703261
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
Trial: NCT02989467
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
Trial: NCT01771809
Drug: 225mg SHP647 (PF-00547659)
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg sterile liquid injected subcutaneously every 4 weeks.
Trial: NCT00995033
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
Trial: NCT03490539
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablets
Trial: NCT01215929
Drug: Dextroamphetamine
RxNorm normalized name: Dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.
Trial: NCT00369629
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m\^2.
Trial: NCT00369629
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m\^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m\^2.
Trial: NCT02406014
Drug: Ingenol Mebutate Gel, 0.015%
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
Trial: NCT01238627
Drug: Nicotine Sublingual Tablet Mint (NSTM)
RxNorm normalized name: nicotine Sublingual Tablet
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of an experimental NSTM, with a 36-hour washout between visits
Trial: NCT01238627
Drug: Marketed Nicotine Tablet
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
Trial: NCT02866695
Drug: ingenol mebutate gel 0.015%
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ingenol mebutate gel 0.015% to be applied on treatment area
Trial: NCT01129583
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
Trial: NCT01129583
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
Trial: NCT04043624
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: regimen of lidocaine administration of 1.5 mg/kg, IV bolus, followed by continuous infusion at 2 mg/kg/h
Trial: NCT04043624
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV bolus of saline, followed by continuous infusion of saline
Trial: NCT01627834
Drug: Ropinirole
RxNorm normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01055652
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg, oral, once daily
Trial: NCT04088630
Drug: Fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset
Trial: NCT04088630
Drug: Open-label Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of 0.5 mg fingolimod through an NGT or Dobhoff tube within 24 hours of symptom onset
Trial: NCT00057980
Drug: epirubicin hydrochloride
RxNorm normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00170001
Drug: Nexium
RxNorm normalized name: Nexium
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg bid dosing
Trial: NCT00170001
Drug: Sugar Pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg BID
Trial: NCT03390101
Drug: BCD-085 Q2W
RxNorm normalized name: anacaulase-bcdb
DrugBank: Anacaulase (DB17449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54.
Trial: NCT03390101
Drug: BCD-085 Q4W
RxNorm normalized name: anacaulase-bcdb
DrugBank: Anacaulase (DB17449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.
Trial: NCT02446171
Drug: Naloxegol 25 mg tablet, crushed, suspended in water, given orally
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
Trial: NCT03175029
Drug: TAC-302
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.
Trial: NCT02446171
Drug: Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
Trial: NCT02446171
Drug: Naloxegol 25 mg (10 mL oral solution)
RxNorm normalized name: naloxegol 25 MG
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: naloxegol 25 mg (10 mL oral solution)
Trial: NCT02446171
Drug: Naloxegol 25 mg tablet, given orally
DrugBank: Naloxegol (DB09049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: naloxegol 25 mg (1 tablet) whole tablet, given orally
Trial: NCT02122601
Drug: LBSA0103 (BDDE cross-linked sodium hyaluronate gel)
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00136383
Drug: paroxetine versus duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00102778
Drug: Kaletra (lopinavir/ritonavir)
RxNorm normalized name: lopinavir / ritonavir Oral Tablet [Kaletra]
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02527200
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
Trial: NCT06365762
Drug: Saline Solution (Placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03164980
Drug: Trabectidin (Yondelis)
RxNorm normalized name: trabectedin Injection [Yondelis]
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel
Trial: NCT02171910
Drug: Doxapram
RxNorm normalized name: Doxapram
DrugBank: Doxapram (DB00561)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04124497
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Daratumumab 16 mg/kg intravenously at following schedule:~* cycle 1 and 2: days 1, 8, 15, and 22~* cycle 3 through 6: days 1, and 15~* from cycle 7 until disease progression: day 1.
Trial: NCT04124497
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg once daily on days 1-21
Trial: NCT04124497
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (\>75 years old) on days 1, 8, 15 and 22
Trial: NCT00408941
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00408941
Drug: Prilocaine
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03740893
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PART 1: Pre-operative exposure to 300mg of olaparib to be administered orally twice daily on Days 1-14 of the WOP.~PART 2: 12 months post-operative exposure to 300mg olaparib (2 x 150mg tablets) to be administered orally twice daily on a continuous schedule Day 1-28 of a 28 day cycle.
Trial: NCT03740893
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PART 1: Pre-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of the WOP.~PART 2: 12 months post-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of a 28 day cycle.
Trial: NCT01909791
Drug: Prompt aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
Trial: NCT01576731
Drug: Tenofovir, Emtricitabine, Lopinavir/r
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination drug
Trial: NCT01576731
Drug: Tenofovir, Emtricitabine, Raltegravir
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Combination drug
Trial: NCT01909791
Drug: Deferred aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
Trial: NCT02211911
Drug: Bisacodyl
RxNorm normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02211911
Drug: Sodium picosulfate
RxNorm normalized name: Sodium Picosulfate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00745589
Drug: sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line higher dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
Trial: NCT02969408
Drug: Albuterol Sulfate
RxNorm normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol sulfate will be administered as per the dose and schedule specified in the arm.
Trial: NCT02723071
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
Trial: NCT00954096
Drug: transdermal nicotine patch (7mg)
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
Trial: NCT01147627
Drug: exenatide injection
RxNorm normalized name: exenatide Injection
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
Trial: NCT01147627
Drug: Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R
RxNorm normalized name: Insulin lispro protamine recombinant
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
Trial: NCT01147627
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
Trial: NCT00023426
Drug: rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00076375
Drug: Nanocrystalline silver cream (NPI)
RxNorm normalized name: silver sulfadiazine Topical Cream
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03859973
Drug: BI 425809
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT01331213
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: FDA approved medication (capsules) at 200mg dose.
Trial: NCT00422513
Drug: methoxy polyethylene glycol-epoetin beta
RxNorm normalized name: Methoxy polyethylene glycol-epoetin beta
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120-360 micrograms intravenous (iv) monthly, starting dose
Trial: NCT00422513
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prescribed, iv, 3 times weekly
Trial: NCT01160419
Drug: Docetaxel 50 mg/m2, 1-hour-Infusion, day 1
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2, 1-hour-Infusion, day 1
Trial: NCT01160419
Drug: Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m², 2-hour-Infusion, day 1
Trial: NCT00858572
Drug: STA-9090 (ganetespib)
RxNorm normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy agent
Trial: NCT03897439
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.
Trial: NCT03897439
Drug: Varenicline Tartrate
RxNorm normalized name: Varenicline tartrate
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VAR will be dispensed 0.5 mg once daily on Days 1-3, 0.5 mg twice daily on Days 4-7, and 1 mg twice daily from Day 8 through the end of treatment.
Trial: NCT03897439
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BUP will be dispensed 150 mg once daily on Days 0-3 and then 150 mg twice daily from Day 4 through optimization or the end of treatment.